je.st
news
Premarket Biotech Digest: Junk Bonds, Gilead Hep C Sales, Keytruda Approval
2015-10-05 16:28:10| Biotech - Topix.net
According to the Financial Times , Valeant Pharmaceuticals , Endo International and Mallinckrodt were among the companies that saw their bonds take a significant hit after the price gouging issue was raised by Democratic presidential candidate, Hillary Clinton. The M&A frenzy in the healthcare sector has been partly fueled by cheap availability of debt.
Tags: sales
approval
bonds
digest
Category:Biotechnology and Pharmaceuticals